Pembrolizumab monotherapy for non-small cell lung cancer (NSCLC): can patient stratification be improved in the UK Tayside population? A retrospective cohort study

OBJECTIVE: Pembrolizumab is a programmed cell death protein-1 (PD-1) inhibitor used to treat advanced patients with non-small cell lung cancer (NSCLC) with a programmed cell death ligand-1 (PD-L1) tumour proportion score (TPS) ≥50. Further sub-division of TPS-based stratification has not been evalua...

Descripción completa

Detalles Bibliográficos
Autores principales: Mander, Emily Susannah, Merrick, Christopher Brian, Nicholson, Hugh Adam, Lord, Hannah Kate, Ferguson, Michelle Jane, Smith, Gillian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10668179/
https://www.ncbi.nlm.nih.gov/pubmed/37989364
http://dx.doi.org/10.1136/bmjopen-2023-076715

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10668179/
https://www.ncbi.nlm.nih.gov/pubmed/37989364
http://dx.doi.org/10.1136/bmjopen-2023-076715

Ejemplares similares